<DOC>
	<DOCNO>NCT01380288</DOCNO>
	<brief_summary>The purpose study evaluate compare change cognitive function ( measure ADAS-Cog ) two group patient Alzheimer 's disease ( AD ) associate without white matter change rivastigmine patch therapy .</brief_summary>
	<brief_title>Cognitive Changes Alzheimer 's Disease Patients Associated With Without White Matter Changes After Rivastigmine</brief_title>
	<detailed_description>Acetylcholinesterase inhibitor ( AChEIs ) increase amount acetylcholine ACh receptor within brain , primary medication use treat AD . Alzheimer 's disease patient frequently associate mild moderate white matter change MR imaging . The impact whiter matter change efficacy cognition , functional ability , behavioral psychiatric symptom caregiver burden probable Alzheimer 's disease well know . There study efficacy rivastigmine patient mild moderate Alzheimer 's disease associate without vascular risk factor . Recently , rivastigmine patch demonstrate efficacy comparable high dos rivastigmine capsule , markedly improve tolerability profile . The investigator hypothesize rivastigmine patch provide benefit AD patient white matter change compare without white matter change . Possible explanation favorable benefit AD white matter change rivastigmine may act Alzheimer 's vascular pathology contribute dementia , provide additive treatment effect patient suffer condition concurrently . To Knowledge , study clinical trial compare change cognitive function , ADL , BPSD caregiver burden two group patient Alzheimer 's disease associate without white matter change rivastigmine transdermal patch therapy .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>AD NINCDSADRDA criterion , mild moderate probable AD without mild moderate whiter matter lesion , exclude multiple large vessel infarct single , strategically place infarct ( angular gyrus , thalamus , basal forebrain , territory posterior anterior cerebral artery ) MRI scan ( within 12 month ) MMSE score : 10 26 screen Hachinski score â‰¤ 4 No clinically significant laboratory abnormality , thyroid disease , vitamine B12 deficiency folic acid deficiency Current evidence history neurological , psychiatric illness could contribute dementia Subjects clinical significant cardiovascular disease , stroke , pulmonary disease medical disease past 6 month History cancer within last 5 year Subjects evidence history clinically significant allergic reaction AchEI drug Subjects significant visual hearing difficulty</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>rivastigmine patch</keyword>
	<keyword>white matter change</keyword>
</DOC>